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Abstract objectives In high-tuberculosis (TB)-endemic countries, comorbidity of pulmonary TB in
hospitalised patients with non-communicable diseases is well documented. In this study, we evaluated
the use of the Xpert MTB/RIF assay for the detection of concomitant pulmonary TB in patients
admitted to the University Teaching Hospital, Lusaka, Zambia, with a primary obstetric or
gynaecological condition.
methods The Study population were inpatients admitted with a primary obstetric or gynaecological
problem who had a concomitant cough and were able to expectorate a sputum sample. Sputum
samples from 94 patients were analysed for the presence of Mycobacterium tuberculosis (M.tb) by
standard smear microscopy, MGIT culture, MGIT drug-susceptibility testing (DST) and the Xpert
MTB/RIF assay. The sensitivity and specificity of the Xpert MTB/RIF assay were evaluated against
the culture gold standard.
results Twenty-six of 94 (27.7%) patients had culture-confirmed pulmonary TB. The Xpert MTB/
RIF assay had a sensitivity of 80.8% [95% CI: 60.0–92.7%]) compared against MGIT culture. The
Xpert MTB/RIF assay was more sensitive than sputum smear microscopy (21/26 (80.8%) vs. 13/26
(50.0%), P = 0.02) and detected an additional eight culture-confirmed cases. Culture DST analysis
identified two monoresistant M.tb strains: one resistant to rifampicin (rifampicin sensitive by the
Xpert MTB/RIF assay) and one to ethambutol. HIV infection was linked with a 3-fold increase in
risk of TB, accounting for 87.5% (21/24) of TB cases. 50% of cases presented as comorbidities with
other communicable diseases (CDs) and non-communicable diseases (NCDs).
conclusions As an alternative to sputum microscopy, the Xpert MTB/RIF assay provides a
sensitive, specific and rapid method for the diagnosis of pulmonary TB in obstetric or gynaecological
inpatients. Pulmonary TB is an important cause of concomitant comorbidity to the obstetric or
gynaecological condition necessitating admission. TB and HIV comorbidities with other
communicable and non-communicable diseases were also common. More proactive screening for TB
comorbidity is required in obstetric and gynaecological wards.
keywords tuberculosis, obstetric, gynaecology, maternal, women, Xpert MTB/RIF assay, sensitivity,
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Introduction
WHO estimates that tuberculosis (TB) killed 500 000
women in 2011, of which 200 000 cases were associ-
ated with HIV co-infection (WHO 2012). In sub-Saha-
ran Africa (SSA), TB causes 15–34% of non-obstetric
maternal deaths (Ahmed et al. 1999; Khan et al. 2001;
Menendez et al. 2008; Black et al. 2009). African
women of child-bearing age carry the highest HIV/TB
codisease burden (WHO 2011a,b). Maternal and child-
hood TB are epidemiologically linked (Batra et al.
2012), and there is a close association between mater-
nal TB and post-partum infant morbidity and mortality
in children born to both HIV-infected (Cotton et al.
2008; Gupta et al. 2011) and HIV-uninfected women
(Tripathy 2003; Lin & Chen 2010). In HIV-infected
women, multivariate analysis has shown that maternal
TB infection was independently linked with increased
risk of mother-to-child transmission of HIV (Gupta
et al. 2011). The risk of TB is 24-fold higher in HIV-
infected infants (Hesseling et al. 2009) who are at
increased risk of TB-associated mortality (Pillay et al.
2001). Pregnancy is an immunosuppressed state and a
risk factor for developing active TB (McNerney et al.
2012).
Tuberculosis comorbidity with other communicable
diseases and non-communicable disorders is well
described, and there are calls for more proactive
screening for TB at all points of care (Bates et al.
2012). TB comorbidity in women requiring obstetric or
gynaecological inpatient care in high TB and HIV ende-
mic countries may be easily overlooked because the
focus of the admitting physician is on the primary
obstetric or gynaecological reason necessitating admis-
sion. In addition, non-specific symptoms of active TB
such as fatigue or night sweats are commonly associ-
ated with pregnancy, during and after childbirth, or in
chronic gynaecological infectious or non-communicable
diseases (Chang et al. 2012). Furthermore, the low sen-
sitivity of sputum smear microscopy and the opera-
tional constraints of mycobacterial culture mean that
not all TB cases are identified (McNerney et al. 2012).
Several new technologies for the rapid diagnosis of TB
are now commercially available such as the Xpert
MTB/RIF assay (Lawn et al. 2013). In this study, we
evaluated the use of the Xpert MTB/RIF assay for the
detection of concomitant pulmonary TB in patients
admitted to the University Teaching Hospital, Lusaka,
Zambia, with a primary obstetric or gynaecological
disorder.
Materials and methods
Ethics approval
This study was approved by the Biomedical Research
Ethics Review Committee of the University of Zambia,
School of Medicine, Lusaka. All study participants gave
written informed consent, and the study was conducted
in full accordance with all the ethics committee’s guide-
lines.
Design and aims
This was a descriptive, prospective study to evaluate the
use of the Xpert MTB/RIF assay for the detection of
concomitant or undiagnosed pulmonary TB and drug-
resistant TB in patients admitted primarily for an obstet-
ric or gynaecological disorder to the University Teaching
Hospital, Lusaka, Zambia.
Patient recruitment
Patients admitted during the previous 24 h to the obstet-
rics or gynaecology wards were eligible for recruitment.
Admission criteria were patients who had a cough and
could produce a sputum sample unaided (without induc-
tion). Patients already on TB treatment were excluded.
Informed consent was obtained from all the study partici-
pants. Clinical details of all the participants including the
diagnosis that necessitated hospital admission were
recorded.
Definitions
Smear positive indicates presence of acid-fast bacilli
(AFBs) in at least one sputum specimen on sputum smear
microscopy. Smear negative means absence of AFBs in
sputum specimens on sputum smear microscopy. Culture
positive refers to a positive MGIT culture with a positive
TBcID confirmatory test result and negative blood agar
test. Culture negative denotes a negative MGIT culture
or positive MGIT culture with a negative TBcID confir-
mation test result.
Sample collection and laboratory processing
Patients with a cough, having given their consent, were
requested to provide up to three sputum samples (spot-
morning-spot). This was supervised by dedicated clinical
staff in the wards. Sample decontamination, fluorescent
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smear microscopy, MGIT culture and phenotypic drug-
susceptibility testing were performed as described previ-
ously (O’Grady et al. 2012).
Xpert© MTB/RIF assay
0.5 ml of concentrated decontaminated sputum was
added to a 15-ml Falcon tube in a 1:3 ratio with the sam-
ple reagent (0.5 ml of sputum sample to 1.5 ml of sample
reagent), and the resulting mixture added to the Xpert
MTB/RIF assay cartridge and then run in the machine in
accordance with the manufacturers guidelines (Lawn
et al. 2013). ‘Error’ results were repeated.
Data analysis
Two dedicated laboratory personnel blinded to all clinical
recruitment, and sample labelling data processed all sam-
ples. Clinical and laboratory data were compiled in a
database using Epidata software. Analysis was under-
taken using SPSS version 18 (IBM, Armonk, NY, USA).
The sensitivity, specificity and predictive values of Xpert
MTB/RIF assay were calculated with 95% confidence
intervals (CI) and compared with smear microscopy using
Pearson chi-squared test. Risk factors were evaluated by
multivariate binary logistic regression.
Results
Study group
Ninety-eight inpatients consented to take part in the
study and provided sputum for microbiological TB analy-
sis. Four patients were excluded from the analysis (two
specimens misplaced, and two cultures were contami-
nated), and so, the results from a total of 94 patients
were analysed (Figure 1). 67.0% (63/94) of recruited
women were pregnant or <6 weeks post-natal when
recruited, and 33.0% (31/94) were not pregnant or
post-natal. Median age was 28 years (IQR: 24–32). HIV
status was available for 84 patients, and HIV prevalence
was 73.8%. 11 patients had a history of TB treatment,
10 of whom were HIV positive and one was of unknown
HIV status (Table 1). The primary admission diagnosis
given by the attending physician was recorded. Suspicion
of TB alone was noted for 25.5% (24/94) of patients,
with an additional 30.9% (29/94) having an admission
diagnosis of pneumonia and suspected TB. The remaining
41 patients presented with a range of admission diagno-
ses including 29.8% (28/94) with other communicable
disease conditions and 13.8% (13/94) with non-commu-
nicable conditions (11 with clearly defined NCDs, the
majority of which were cancer) (Table 2).
Performance of the Xpert MTB/RIF assay for detecting
pulmonary tuberculosis
Of 26 culture-confirmed TB cases, the Xpert MTB/RIF
assay detected 21 of 26 culture-confirmed cases giving a
sensitivity of 80.8% [95% CI: 60.0–92.7%]. With respect
to specificity, the assay identified 66 of 68 culture-nega-
tive samples, giving a specificity of 97.1% [95% CI:
88.8–99.5%] (Table 3). The Xpert MTB/RIF assay was
significantly more sensitive than microscopy (21/26
(80.8%) vs. 13/26 (50.0%), P = 0.02) and detected an
additional eight culture-confirmed cases. Numbers were
low, but stratification of Xpert MTB/RIF assay perfor-
mance by HIV status found the assay to be 100% sensi-
tive and specific in HIV-negative patients, with possible
(but not statistically significant) poorer performance in
HIV-infected patients (Table 3). The Xpert MTB/RIF
assay detected no cases of rifampicin resistance, failing to
detect one rifampicin-resistant strain identified by culture
DST. Two monoresistant Mycobacterium tuberculosis
Consented to take part in study and expectorated     
sputum samples n = 98 patients 
2 samples misplaced 
2 Contaminated Cultures 
Included in the analysis n = 94
HIV infected:  
n = 62  
TB cases = 21 (33.9%) 
HIV uninfected: 
n = 22 
TB cases = 3 (13.6%) 
Unknown HIV status:  
n = 10 
TB cases = 2 (20%) Figure 1 Recruitment flow diagram
detailing TB and HIV status.
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strains were detected in total, one rifampicin and one eth-
ambutol resistant. No MDR-TB cases were identified by
culture DST analysis (data not shown). Three samples
initially gave an error on the Xpert MTB/RIF assay.
These were repeated and found to be negative.
Potential risk factors
TB prevalence within HIV-infected patients was nearly
3-fold higher than that in HIV-uninfected patients
(33.9% (21/62) vs. 13.6% (3/19)), with an associated
3-fold increase in risk of TB infection amongst HIV-
infected patients (OR 3.244 [95% CI 0.861–12.221])
(P = 0.082) (Table 2). Multivariate binary logistic regres-
sion analysis (adjusting for the effect of HIV) demon-
strated that the risk of TB was unaffected by patient age
(OR 0.990 [0.925–1.060], P = 0.773), previous treatment
history (OR 0.471 [0.090–4.469], P = 0.927) or preg-
nancy (OR 1.909 [0.649–5.612], P = 0.240) (Table 2).
42.3% (11/26) of TB cases were detected in patients with
no other reason for admission other than suspected TB
(Table 1). 50% (13/26) of TB cases were detected in
patients with evidence of comorbidity with other commu-
nicable diseases: eight cases of pneumonia, two cases of
sepsis (one septic abortion and one case of puerperal sep-
sis in HIV/AIDS), two cases of pelvic inflammatory dis-
ease (likely bacterial infection) and one case of malaria.
The two remaining cases included one patient with acute
cephalopelvic disproportion with suspected abdominal
TB and a patient with puerperal psychosis (Table 1).
Discussion
The key findings of this study are that in inpatients
admitted to the obstetrics and gynaecology wards at
UTH, Lusaka, Zambia, (i) pulmonary TB is an important
incidental cause of concomitant comorbidity to the
obstetric or gynaecological condition necessitating admis-
sion, (ii) as an alternative to sputum microscopy and cul-
ture, the Xpert MTB/RIF assay provides a sensitive,
Table 1 Study group descriptives for all patients and those with culture-confirmed TB
Within all patients (n = 94)
Within culture-confirmed TB cases
(n = 26)
Proportion 95% CI Proportion 95% CI
Age in years (IQR) 28 (24–33) NA 29 (26–33) NA
HIV status*
HIV infected 62/84 (73.8%) [63.5–73.8%] 21/24 (87.5%) [69.0–95.7%]
HIV uninfected 22/84 (26.2%) [18.0–36.5%] 3/24 (13.3%) [4.3–31.0%]
Pregnancy status
Pregnant or <6 w post-natal 63/94 (67.1%) [57.0–75.7%] 20/26 (76.9%) [58.0–89.0%]
Not pregnant or post-natal 31/94 (33.0%) [24.3–43.0%] 6/26 (23.1%) [11.0–42.1%]
Treatment history†
Previously treated 11/86 (12.8%) [7.3–21.5%] 2/22 (9.1%) [2.5–27.8%]
Not previously treated 75/86 (87.2%) [78.5–92.7%] 20/22 (90.1%) [72.1–97.5%]
Admission diagnosis
Pneumonia 29/94 (30.9%) [22.4–40.8%] 8/26 (30.8%) [16.5–50.0%]
Suspected PTB 24/94 (25.5%) [17.8–35.2%] 12/26 (42.3%) [28.8–64.5%]
PID 11/94 (11.7%) [6.6–19.8%] 2/26 (7.7%) [2.1–24.1%]
Cancer 8/94 (8.5%) [4.4–15.9%] 0/26 (0%) [0–12.9%]
Sepsis 6/94 (6.4%) [3.0–13.2%] 2/26 (7.7%) [2.1–24.1%]
Malaria 4/94 (4.3%) [1.7–10.4%] 1/26 (3.8%) [0.7–19.0%]
EPTB 4/94 (4.3%) [1.7–10.4%] 1/26 (3.8%) [0.7–19.0%]
CCF 3/94 (3.2%) [1.1–9.0%] 0/26 (0%) [0–12.9%]
UTI 2/94 (2.1%) [0.6–7.4%] 0/26 (0%) [0–12.9%]
Pre-eclampsia 1/94 (1.1%) [0.2–5.8%] 0/26 (0%) [0–12.9%]
Puerperal psychosis 1/94 (1.1%) [0.2–5.8%] 1/26 (3.8%) [0.7–19.0%]
Vulval Filariasis 1/94 (1.1%) [0.2–5.8%] 0/26 (0%) [0–12.9%]
IQR, interquartile range; PID, pelvic inflammatory disease; EPTB, extrapulmonary tuberculosis; CCF, congestive cardiac failure; UTI,
urinary tract infection.
*HIV status was available for 84 of 94 cases.
†Treatment history was unavailable for 8 cases.
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specific and rapid method for diagnosis of pulmonary
TB, and (iii) comorbidity of TB with HIV, other commu-
nicable and non-communicable diseases was common.
The main limitation of this study was the relatively small
number of patients. We have previously shown that TB
can be detected in up to 10% of patients capable of pro-
ducing sputum who are not clinically suspected of having
pulmonary TB (Bates et al. 2012). As we only recruited
patients with a cough, our data may underestimate the
true prevalence of TB amongst obstetric and gynaecologi-
cal admissions. Low numbers impaired the evaluation of
the Xpert MTB/RIF assay to detect rifampicin resis-
tance.
National TB programmes in high HIV/TB burden
countries require data from different patient groups to
inform on how best to incorporate the Xpert MTB/RIF
assay into their diagnostic algorithms. In obstetric and
gynaecological inpatients, we report a sensitivity of
80.8% (95% CI: 60.0–92.7%) and a specificity of 97.1%
(95% CI: 88.8–99.5%), which is comparable with previ-
ous findings from the internal medicine wards at our cen-
tre (O’Grady et al. 2012), and elsewhere (Chang et al.
2012). With the high throughput of obstetrics and gynae-
cology wards, the Xpert MTB/RIF assay could be a
useful tool to rapidly screen for TB during the opportu-
nity that presents during the obstetric or gynaecological
Table 2 Univariate and multivariate risk factor analysis for culture-positive TB infection in obstetric and gynaecological inpatients
Risk factor
Culture-positive TB Univariate Multivariate*
Proportion 95% CI OR [95% CI] P = OR [95% CI] P =
HIV status
HIV infected 33.9% (21/62) [23.3–46.3%] 3.244 [0.861–12.22] 0.082 3.244 [0.861–12.22] 0.082
HIV uninfected 13.6% (3/19) [5.5–37.6%] – – – –
Pregnancy status
Pregnant or <6 w post-natal 31.7% (20/63) [21.6–44%] 1.938 [0.687–5.466] 0.211 1.909 [0.649–5.612] 0.240
Not pregnant or post-natal 19.4% (6/31) [9.2–36.3%] – – – –
Treatment history
Previously treated 18.2% (2/11) [5.1–47.7%] 0.611 [0.121–3.074] 0.550 0.471 [0.090–4.469] 0.373
Not previously treated 26.7% (20/75) [18.0–37.6%] – – – –
Age group† 1.001 [0.944–1.060] 0.983 0.990 [0.925–1.060] 0.773
15–20 years 0% (0/7) [0–35.4%] – – – –
21–25 years 27.3% (6/22) [13.2–48.2%] – – – –
26–30 years 33.3% (12/36) [20.2–49.7%] – – – –
31–35 years 42.9% (6/14) [21.4–67.4%] – – – –
36–40 years 25% (2/8) [7.1–59.1%] – – – –
≥41 years 0% (0/7) [0–35.4%] – – – –
Data are n TB positive/n tested (%) [95% CI], odds ratios (ORs) and p values present results of binary logistic regression analysis.
*Multivariate analysis was controlled for effect of HIV.
†Age was analysed as a continuous variable but is displayed as grouped to illustrate the age distribution of TB cases.
Table 3 Xpert MTB/RIF assay performance compared with MGIT culture and smear microscopy
Sensitivity (95% CI) Specificity (95% CI) PPV NPV
Xpert MTB/RIF assay versus MGIT
All patients* 21/26 (80.8%) [60.0–92.7%]† 66/68 (97.1%) [88.8–99.5%] 91.3% [70.5–98.5%] 93.0% [83.7–97.4%]
HIV negative 3/3 (100%) [31.0–100%] 19/19 (100%) [79.1–100%] 100% [31.0–100%] 100% [79.1–100%]
HIV positive 17/21 (80.1%) [57.4–93.7%]‡ 39/41 (95.1%) [82.2–99.2%] 89.5% [65.5–98.2%] 90.7% [76.9–97.0%]
Sputum smear microscopy versus MGIT
All patients 13/26 (50.0%) [30.4–69.6%]† 66/66 (100%) [93.3–100%] 100% [71.7–100%] 84.0% [73.8–90.8%]
HIV negative 2/3 (66.7%) [12.5–98.2%] 19/19 (100%) [79.1–100%] 100% [19.8–100%] 95.0% [73.1–99.7%]
HIV positive 10/21 (47.6%) [26.4–69.7%]‡ 41/41 (100%) [89.3–100%] 100% [65.5–100%] 78.8% (65.5–88.5%]
Data displayed as number correct/number tested, (%) [95% CI]; PPV, positive predictive value; NPV, negative predictive value.
*The Xpert MTB/RIF assay gave repeat errors in 3 samples and is excluded from this analysis. Fisher’s exact test: †P = 0.02,
‡P = 0.03.
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admission or consultation. It may also help distinguish
TB from other co-infections and comorbidities and ensure
prompt initiation of TB therapy, reducing the risk of
transmission to the baby and other family members. The
one case of rifampicin resistance detected by DST was
missed by the Xpert MTB/RIF assay. False-negative
rifampicin resistance has been well documented, and
larger studies within high MDR-TB prevalence countries
are required to evaluate whether the manufacturer has
successfully addressed this issue (O’Grady et al. 2012;
Lawn et al. 2013).
The prevalence of HIV infection within our study pop-
ulation was 73.4%. Whilst our study sample was small
and major conclusions of HIV prevalence cannot be
drawn, this high HIV burden amongst obstetric and
gynaecological inpatients with suspected TB is compara-
ble to that seen amongst females on the adult general
internal medicine wards at UTH (Bates et al. 2012;
O’Grady et al. 2012). This focus of HIV-associated TB
cases highlights the need for broader active case finding
in asymptomatic and lower-risk patient groups with com-
munity-based studies in Zambia previously showing that
as little as 43% of TB cases occur in patients who would
be classically defined as TB suspects (Ayles et al. 2009).
In our study, there was a trend for HIV infection to be
linked with a threefold increase in risk of TB infection
compared with a 2-fold increase in risk of TB infection
amongst HIV-infected patients on the internal medicine
wards (Bates et al. 2012). A large community-based
study of antenatal attendants in South Africa also found
TB rates to be 3-fold higher amongst HIV-infected
women (Gounder et al. 2011). We did not detect any sig-
nificant decrease in risk of TB infection, with increasing
age as shown previously (Bates et al. 2012), but this may
likely be due to the younger age profile of our study
group: median age of 28 (IQR: 24–33) vs. 35 (IQR:
28–43) (Bates et al. 2012), Mann–Whitney U-test,
P < 0.001).
One of the challenges at busy, high-turnover referral
hospitals is the focus on addressing the immediate obstet-
ric or gynaecological reason for admission, whilst con-
comitant comorbidities with chronic communicable
diseases like TB can be easily overlooked (Marais et al.
2013). High levels of TB comorbidity with other commu-
nicable and non-communicable disease have been previ-
ously documented amongst general internal medicine
inpatients at the University Teaching Hospital in Lusaka
(Bates et al. 2012). We hence sought to assess to what
degree TB cases presented as comorbidities on the obstet-
ric and gynaecological wards. We documented five cases
of TB comorbidity with infectious diseases including pel-
vic inflammatory disease (PID), bacterial sepsis and
malaria. 11.7% (11/94) of the recruited patients had a
clearly defined non-communicable disease (cancer and
congestive cardiac failure), and active TB was not
detected in these cases. We detected 20 cases of pulmo-
nary TB within women who were either pregnant or
<6 weeks post-natal. We did not conduct follow-up to
assess the risk of neonatal TB infection in the women
recruited, but one South African study detected TB in
16% of neonates born to mothers with suspected or pro-
ven TB (Bekker et al. 2012). The majority of neonatal
admissions have feeding tubes inserted, which presents an
excellent opportunity for TB screening without the need
for additional invasive sampling, possibly using the
Xpert MTB/RIF assay, which has been demonstrated to
perform well on gastric aspirate at our site (Bates et al.
2013).
Conclusions
The Xpert MTB/RIF assay provides a sensitive, specific
and rapid method for diagnosis of TB in obstetric or
gynaecological inpatients. Most of the obstetric admis-
sions and during the study were for deliveries with a
short duration of inpatient stay. Similarly, the gynaecol-
ogy admissions were for miscarriages with a similar short
stay. The high TB/HIV co-infection rates in SSA and
presence of TB with HIV comorbidities now call for
more proactive and rapid screening for pulmonary TB
and HIV in obstetric and gynaecological inpatient facili-
ties to provide more optimal and synergistic alignment of
health care for communicable and non-communicable
disorders.
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